Inhibition of FOXO1 not only mitigated myogenic and metabolic abnormalities in ALS myoblast cells but also in other two MN disorders with muscle involvement, such as Spinal Muscular Atrophy (SMA) or Spinal Bulbar Muscular Atrophy (SBMA). Here, FOXO1 is linked to proximal spinal muscular atrophy.